Standard BioTools Q2 2024 GAAP EPS $(0.12) Misses $(0.10) Estimate, Sales $37.205M Miss $48.250M Estimate
Portfolio Pulse from Benzinga Newsdesk
Standard BioTools (NASDAQ:LAB) reported Q2 2024 GAAP EPS of $(0.12), missing the $(0.10) estimate. Sales were $37.205M, missing the $48.250M estimate. Despite the misses, EPS improved by 45.45% and sales increased by 34.48% year-over-year.
July 31, 2024 | 9:37 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Standard BioTools reported Q2 2024 GAAP EPS of $(0.12), missing the $(0.10) estimate. Sales were $37.205M, missing the $48.250M estimate. Despite the misses, EPS improved by 45.45% and sales increased by 34.48% year-over-year.
The company missed both EPS and sales estimates, which is likely to negatively impact the stock price in the short term. However, the year-over-year improvements in EPS and sales may provide some support.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100